Frequently asked questions

Vero is a predictive health company on a mission to end age-related chronic disease. Built on groundbreaking Stanford University research, Vero uses advanced proteomics and machine learning to measure the biological aging of organ systems from a simple blood test. The Vero OrganAge™ test, now enhanced with Cell Clocks™, is the entry point to Vero Compass™ – a biological intelligence platform that translates complex biological signals into clear, actionable insights that help clinicians and individuals intervene earlier and track meaningful improvement over time. Backed by leading scientific and clinical advisors, Vero is building the next era of predictive health to empower people to prevent disease and extend healthspan.

Vero was co-founded by Tony Wyss-Coray, PhD, whose Stanford University lab pioneered proteomic organ-aging research published in Nature (2023) and Nature Medicine (2025). This was followed by his breakthrough "Cell Clock" research in Nature Medicine (2026), which extended these discoveries to the cellular level, providing unprecedented resolution into the exact biological mechanisms driving aging and future disease risk.

The scientific and clinical advisors are Eric Verdin, MD (Buck Institute for Research on Aging), Michael Doney, MD (Biograph), Christin Glorioso, MD, PhD (NeuroAge Therapeutics), and Helen Messier, MD, PhD (Altum Medical).

Vero works alongside your annual physical and your doctor, not in place of them.

A standard physical checks basic blood markers against broad population averages to identify active disease or dysfunction. Vero uses advanced proteomics to analyze thousands of proteins to evaluate organ and cellular health before routine markers shift out of range.

Instead of waiting for a symptom or diagnosis, Vero provides your clinician with predictive insights to guide targeted preventive care and measure whether interventions are actually changing your health trajectory over time.

Vero is not yet broadly available to the public, with full consumer availability planned for 2027. Currently, Vero’s OrganAge™ is accessible exclusively through select clinical research partnerships.

You can reserve priority access by joining the waitlist at verobioscience.com. Waitlist members receive first notice when new study opportunities open up and when availability expands.

‍

OrganAge™ is a blood test that measures biological health at the organ and cellular level. It goes beyond single-number age scores to pinpoint vulnerabilities so you can take action where it matters most.

Vero Compass™ is Vero’s biological intelligence platform that translates biological, clinical, and wearable data into actionable health insights. Built for both consumers and clinicians, it predicts where an individual’s health is heading, guides precision interventions designed to slow or reverse organ aging, and measures how each organ responds over time. This creates a continuous feedback loop to track and extend healthspan.

Vero Compass is in development and is not a diagnosis or a treatment plan. People on the waitlist get first access.

Cell Clocks™ apply the same idea as organ aging but with cellular-level resolution. Instead of estimating an age for an organ, they estimate age for a cell type — neuronal, immune, glial, endocrine, epithelial and musculoskeletal cells among them.

The published work behind them modelled over 40 cell types from more than 7,000 plasma proteins measured in 60,542 people across three cohorts, and found that 20–25% of individuals showed accelerated ageing in a single cell type. Those signatures tracked disease status and predicted incident disease and mortality over 15 years of follow-up. (Nature Medicine, 2026)

Proteomics is the measurement of the proteins circulating in your blood and their functions. Where your genome is a fixed set of instructions, your proteome is what those instructions are producing right now — the full set of proteins in your body at this moment. It shifts with age, illness, sleep, training, medication and stress.

A standard blood panel measures hundreds of proteins one at a time. A proteomic panel measures thousands in a single run of the same sample. OrganAge™ reads 11,000+.

Read the full explainer →

The link is made statistically. Vero's models record which tissues produce which proteins and in what quantity. A protein counts as organ-enriched when one tissue produces it at several times the rate of any other.

DNA methylation clocks measure slow-moving chemical marks on DNA, yielding a single overall age score. Proteomic clocks measure circulating proteins from tissues, providing real-time, organ-specific resolution for systems like your heart, brain, and immune. While methylation tracks general biological age, proteomics measures how individual organs change and respond to interventions over time.

In a 2026 Nature Medicine review paper, Drs. Eric Topol and Tony Wyss-Coray highlighted proteomic organ clocks as a major advance, shifting aging science from broad summary scores to targeted precision care.

‍

Three peer-reviewed papers underpin the approach. The 2023 Nature study covered 5,676 adults aged 27 to 104 across five independent cohorts and modelled 11 organs. The 2025 Nature Medicine study tested it at population scale in roughly 44,500 people in the UK Biobank, where brain age was the single strongest predictor of mortality risk in that dataset. The 2026 Nature Medicine paper extended it to over 40 cell types in 60,542 people.

That is a strong and growing research base, and it is still research. Through ongoing clinical studies, Vero continues to advance the validation of OrganAge™ as an established clinical biomarker of healthspan.

Vero OrganAge™ is not a diagnostic tool and may not detect acute or short-term changes. Results should be interpreted in the context of your history and other clinical data.

Signing up for the waitlist reserves your priority access to Vero’s OrganAge™ and Vero Compass™. Waitlist members are the first to know whenever new clinical research studies open up or when early platform access expands. You can unsubscribe at any time, and you are under no obligation to continue with your membership when it becomes available.

Vero’s OrganAge™ is currently accessible through exclusive clinical research partnerships -- including a recent collaboration with Biograph -- ahead of broad consumer availability in 2027. We are now opening our waitlist to grant priority access for upcoming studies with clinical partners across the U.S. When a study opens that waitlist members can join, we’ll notify the list first. If you are interested in participating in a study, contact us at hello@verobioscience.com.